← Eichor
Condition: Systemic Autoimmune Diseases Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Systemic Autoimmune Diseases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
Phase N/A · 1 location(s) · Children's National Research Institute · NCT04833465LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NA · 14 location(s) · Heinrich-Heine University, Duesseldorf · NCT05714930Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787Systemic Lupus Erythematosus in Gullah Health
Phase N/A · 1 location(s) · Medical University of South Carolina · NCT00756769Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, a
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT03510442Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Sy
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT05927688tDCS in Post-Acute COVID-19 Patients With SARDs
NA · 1 location(s) · University of Sao Paulo · NCT04890483US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Phase 1 · 3 location(s) · HC Biopharma Inc. · NCT06657703Exosomes Proteomic for Sjogren's Syndrome and Dry Eye Syndrome
Phase N/A · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT06771427A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Phase 2 · 2 location(s) · Guangdong Hengrui Pharmaceutical Co., Ltd · NCT07299422A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Duke Lupus Registry
Phase N/A · 1 location(s) · Duke University · NCT00512694Dose Response of Exercise for Arthritis Management
NA · 1 location(s) · University of South Carolina · NCT06880653Deciphering the Genetic Architecture of Autoimmune Diseases
Phase N/A · 2 location(s) · National Human Genome Research Institute (NHGRI) · NCT06948110Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06316791A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07517250Lupus Landmark Study: A Prospective Registry and Biorepository
Phase N/A · 25 location(s) · Lupus Research Alliance · NCT05934149A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT02257866RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Phase 2 · 82 location(s) · Zenas BioPharma (USA), LLC · NCT06559163Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415Safety of Administering Isoniazid to SLE Patients to Prevent TB
Phase 2/Phase 3 · 1 location(s) · Universitas Padjadjaran · NCT06618573A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.